The loss of tuberin promotes cell invasion through the β-catenin pathway

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 5, 2010, Pages 617-627

  Barnes, Elizabeth A ^a   Kenerson, Heidi L ^a   Mak, Baldwin C ^a   Yeung, Raymond S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Caspase 3; LAM; MMP7; Tuberous sclerosis complex

Indexed keywords

BETA CATENIN; CASPASE 3; MATRILYSIN; TUBERIN; MUTANT PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TUMOR; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; TRANSCRIPTION INITIATION; ANIMAL; CELL LINE; CELL MOTION; CELL SURVIVAL; CONTACT INHIBITION; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; CASPASE 3; CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CONTACT INHIBITION; FIBROBLASTS; HUMANS; KIDNEY NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASE 7; MUTANT PROTEINS; RATS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 77957377778     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0335OC     Document Type: Article

References (45)

1. Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci 2001;321:17-25.
2. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815.
3. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090. (Pubitemid 30367527)
4. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 2001;164:1537-1540.
5. McCormack F, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, Franz DN. Pulmonary cysts consistent with lymphangioleiomyomatosis are common in women with tuberous sclerosis: genetic and radiographic analysis. Chest 2002;121:61S.
6. Gomez MR. Definition and criteria for diagnosis: tuberous sclerosis complex. Tuberous sclerosis complex: developmental perspectives in psychiatry, 3rd edition. Gomez MR, Sampson JR, Whittemore VH, editors. New York: Oxford University Press; 1999. pp. 10-24.
7. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int 2004;66:924-934.
8. O'Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004;94:853-857.
9. De Pauw RA, Boelaert JR, Haenebalcke CW, Matthys EG, Schurgers MS, De Vriese AS. Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis. Am J Kidney Dis 2003;41:877-883.
10. Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996;335:1275-1280.
11. O'Brien JD, Lium JH, Parosa JF, Deyoung BR, Wick MR, Trulock EP. Lymphangiomyomatosis recurrence in the allograft after single-lung transplantation. Am J Respir Crit Care Med 1995;151:2033-2036.
12. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
13. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 2003;34:95-98.
14. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004;101:17462-17467.
15. Jones KA, Jiang X, Yamamoto Y, Yeung RS. Tuberin is a component of lipid rafts and mediates caveolin-1 localization: role of TSC2 in post-Golgi transport. Exp Cell Res 2004;295:512-524.
16. Jin F, Wienecke R, Xiao GH, Maize JC Jr, DeClue JE, Yeung RS. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA 1996;93:9154-9159.
17. Yeung RS, Xiao GH, Jin F, Lee WC, Testa JR, Knudson AG. Pre-disposition to renal carcinoma in the Eker rat is determined by germline mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 1994;91:11413-11416.
18. Poot M, Rosato M, Rabinovitch PS. Analysis of cell proliferation and cell survival by continuous BrdU labeling and multivariate flow cytometry. Curr Protoc Cytom 2001;7:7-14.
19. Pierce RH, Campbell JS, Stephenson AB, Franklin CC, Chaisson M, Poot M, Kavanagh TJ, Rabinovitch PS, Fausto N. Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line. Am J Pathol 2000;157:221-236. (Pubitemid 30641739)
20. Chen P, McGuire JK, Hackman RC, Kim K-H, Black RA, Poindexter K, Yan W, Liu P, Chen AJ, Parks WC, et al. Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity. Am J Pathol 2008;172:1256-1270. (Pubitemid 351671539)
21. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem 2003;278:5947-5951. (Pubitemid 36800842)
22. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS. Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol 2005;167:107-116.
23. Van de Craen M, Berx G, Van den Brande I, Fiers W, Declercq W, Vandenabeele P. Proteolytic cleavage of beta-catenin by caspases: an in vitro analysis. FEBS Lett 1999;458:167-170. (Pubitemid 29428176)
24. Steinhusen U, Badock V, Bauer A, Behrens J, Wittman-Liebold B, Dorken B, Bommert K. Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 2000;275:16345-16353. (Pubitemid 30366951)
25. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996;272:974-975. (Pubitemid 26259322)
26. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J Biol Chem 1997;272:24735-24738. (Pubitemid 27415637)
27. Barth AI, Pollack AL, Altschuler Y, Mostov KE, Nelson WJ. NH2-terminal deletion of beta-catenin results in stable colocalization of mutant beta-catenin with adenomatous polyposis coli protein and altered MDCK cell adhesion. J Cell Biol 1997;136:693-706.
28. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1752-1753.
29. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
30. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
31. Lemaitre V, D'Armiento J. Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 2006;78:1-10.
32. Shapiro SD, Senior RM. Matrix metalloproteinases: matrix degradation and more. Am J Respir Cell Mol Biol 1999;20:1100-1102.
33. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28:1071-1078.
34. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:267-275.
35. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 2006;231:20-27.
36. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: A quantitative comparison of the activities of 95kDa and 72kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991;277:277-279.
37. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111-118.
38. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-480.
39. Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T, Yamada Y, Costantini F, Wakisaka S, Pacifici M, et al. Developmental regulation of Wnt-beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem 2005;280:19185-19195.
40. Leeman MF, Curran S, Murray GI. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 2003;201:528-534. (Pubitemid 38256401)
41. Goncharova EA, Goncharov DA, Lim PN, Noonan DJ, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006;34:473-480.
42. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002;419:395-399.
43. Nakamoto K, Kuratsu J, Ozawa M. Beta-catenin cleavage in non-apoptotic cells with reduced cell adhesion activity. Int J Mol Med 2005;15:973-979.
44. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 2008;29:541-551. (Pubitemid 351384644)
45. Kenerson H, Folpe AL, Takayama TK, Yeung RS. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol 2007;38:1361-1371. (Pubitemid 47247479)